Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study.

[1]  M. King,et al.  Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin , 2017, Journal of viral hepatitis.

[2]  J. Pawlotsky,et al.  HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals , 2015, Antiviral therapy.

[3]  Brian L. Pearlman,et al.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.

[4]  M. Manns,et al.  Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis , 2014, PloS one.

[5]  M. Manns,et al.  Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial , 2014, The Lancet.

[6]  C. Sarrazin,et al.  HCV RNA Quantification with Different Assays: Implications for Protease-Inhibitor-Based Response-Guided Therapy , 2014, Antiviral therapy.

[7]  Riina Salupere,et al.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.

[8]  Thomas Berg,et al.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.

[9]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[10]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[11]  O. Weiland,et al.  Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. , 2014, Journal of hepatology.

[12]  Eoin Coakley,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[13]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[14]  A. Lok,et al.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.

[15]  H. Wedemeyer,et al.  Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir , 2014, Alimentary pharmacology & therapeutics.

[16]  C. Sarrazin,et al.  The importance of HCV RNA measurement for tailoring treatment duration. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  J. Hayashi,et al.  Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays. , 2013, Antiviral research.

[18]  J. Pawlotsky,et al.  The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA , 2013, Journal of Clinical Microbiology.

[19]  C. Sarrazin,et al.  Second-Generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for Viral Load Monitoring: a Novel Dual-Probe Assay Design , 2012, Journal of Clinical Microbiology.

[20]  R. D. de Knegt,et al.  Performance Evaluation of the New Roche cobas AmpliPrep/cobas TaqMan HCV Test, Version 2.0, for Detection and Quantification of Hepatitis C Virus RNA , 2012, Journal of Clinical Microbiology.

[21]  L. Naeger,et al.  Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment , 2012, Hepatology.

[22]  R. Vilchez,et al.  An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments , 2012, Hepatology.

[23]  M. Ghany,et al.  An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[24]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[25]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[26]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[27]  M. Tell.  European Association for the Study of the Liver (EASL) - 47th International Liver Congress, Barcelona, Spain - April 18 - 22, 2012 , 2012, Drugs of the Future.

[28]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.